MX2022011988A - Nuevos lipidos y composiciones de nanopartículas de estos. - Google Patents
Nuevos lipidos y composiciones de nanopartículas de estos.Info
- Publication number
- MX2022011988A MX2022011988A MX2022011988A MX2022011988A MX2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A MX 2022011988 A MX2022011988 A MX 2022011988A
- Authority
- MX
- Mexico
- Prior art keywords
- lipids
- formula
- nanoparticle compositions
- novel lipids
- capsid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000990P | 2020-03-27 | 2020-03-27 | |
| PCT/US2021/024413 WO2021195529A2 (en) | 2020-03-27 | 2021-03-26 | Novel lipids and nanoparticle compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011988A true MX2022011988A (es) | 2023-01-04 |
Family
ID=77890624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011988A MX2022011988A (es) | 2020-03-27 | 2021-03-26 | Nuevos lipidos y composiciones de nanopartículas de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12534435B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125821A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7746280B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220160647A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115916163A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021241696B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019369A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173126A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296763B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011988A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021195529A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3864163T3 (da) | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| US12534435B2 (en) * | 2020-03-27 | 2026-01-27 | Generation Bio Co. | Lipids and nanoparticle compositions thereof |
| AU2021307952A1 (en) * | 2020-07-17 | 2023-03-02 | Generation Bio Co. | Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| CN118251212A (zh) * | 2021-09-30 | 2024-06-25 | 日油株式会社 | 用于将核酸递送至淋巴管内皮细胞的脂质纳米颗粒 |
| WO2023121964A1 (en) * | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterials comprising disulfides |
| JPWO2023190164A1 (cg-RX-API-DMAC7.html) * | 2022-03-28 | 2023-10-05 | ||
| CA3247022A1 (en) | 2022-03-28 | 2025-07-08 | National University Corporation Chiba University | METHOD FOR PRODUCING LIPID NANOPARTICLES ENCAPSULATED IN A NUCLEIC ACID, METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION CONTAINING SAID LIPID NANOPARTICLES, AND METHOD FOR INTRODUCING NUCLEIC ACID INTO A CELL OR A TARGET CELL |
| WO2023190175A1 (ja) | 2022-03-28 | 2023-10-05 | 日油株式会社 | 末梢血単核細胞へ核酸を送達するための脂質ナノ粒子およびこれを用いて末梢血単核細胞へ核酸を送達する方法 |
| JPWO2023190176A1 (cg-RX-API-DMAC7.html) | 2022-03-28 | 2023-10-05 | ||
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| KR20250038709A (ko) | 2022-07-15 | 2025-03-19 | 니치유 가부시키가이샤 | 지질 나노입자 및 이의 제조 방법, 핵산-캡슐화 지질 나노입자 및 이의 제조 방법, 및 핵산-캡슐화 지질 나노입자를 사용하여 생체에서 획득 면역을 유도하는 방법 |
| KR20250037535A (ko) | 2022-07-15 | 2025-03-17 | 니치유 가부시키가이샤 | 핵산-로딩된 지질 나노입자의 동결건조 조성물 |
| WO2024192528A1 (en) * | 2023-03-22 | 2024-09-26 | Nanovation Therapeutics Inc. | Ionizable anionic lipids |
| WO2024203660A1 (ja) | 2023-03-29 | 2024-10-03 | 国立大学法人東北大学 | 核酸内封脂質ナノ粒子の製造方法 |
| CN116082184B (zh) * | 2023-04-12 | 2023-06-30 | 山东大学 | 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025043146A2 (en) * | 2023-08-24 | 2025-02-27 | Molecular Axiom Inc. | Lipid nanoparticle compositions and methods of using same |
| CN121909024A (zh) | 2023-09-22 | 2026-04-21 | 国立大学法人东北大学 | 包封有核酸的配体修饰脂质纳米颗粒的制造方法 |
| US20260234104A1 (en) * | 2023-12-15 | 2026-08-13 | Xiamen Sinopeg Biotech Co., Ltd. | Degradable cationic lipid containing a disulfide bond and applications thereof |
| WO2025150516A1 (ja) | 2024-01-12 | 2025-07-17 | 日油株式会社 | 核酸内封脂質ナノ粒子を含む凍結組成物 |
| CN117964577B (zh) * | 2024-03-29 | 2024-06-21 | 天津全和诚生物技术有限公司 | 阳离子脂质化合物、其制备方法、包含其的组合物及应用 |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026070952A1 (ja) * | 2024-09-27 | 2026-04-02 | 日油株式会社 | ジスルフィド結合を有する化合物およびその製造方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| CN1882693B (zh) | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| WO2008103276A2 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| EP2310440A4 (en) | 2008-07-10 | 2013-06-05 | Serina Therapeutics Inc | POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS |
| EP3391877A1 (en) | 2010-04-08 | 2018-10-24 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US20120225129A1 (en) | 2010-08-20 | 2012-09-06 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
| WO2012046265A1 (ja) * | 2010-10-05 | 2012-04-12 | トヨタ自動車株式会社 | 推定装置および推定方法 |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| CA2853689C (en) | 2011-11-04 | 2020-06-30 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| WO2013073480A1 (ja) * | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| US9035039B2 (en) * | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| TWI595885B (zh) | 2012-05-02 | 2017-08-21 | 喜納製藥公司 | 包含四galnac之新穎結合物及傳送寡核苷酸之方法 |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| WO2017084987A1 (en) | 2015-11-16 | 2017-05-26 | F. Hoffmann-La Roche Ag | GalNAc CLUSTER PHOSPHORAMIDITE |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| IL261524B2 (en) | 2016-03-03 | 2023-10-01 | Univ Massachusetts | End-capped linear double-stranded DNA for non-viral gene transfer |
| JP2019151589A (ja) * | 2018-03-02 | 2019-09-12 | 国立大学法人北海道大学 | 脂質ナノ粒子 |
| CA3094057C (en) * | 2018-03-27 | 2025-04-08 | Nof Corporation | CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS |
| JP7075256B2 (ja) * | 2018-03-28 | 2022-05-25 | 三菱重工業株式会社 | 配管の余寿命評価方法 |
| CN114929205B (zh) | 2019-09-06 | 2024-09-03 | 世代生物公司 | 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 |
| US12534435B2 (en) | 2020-03-27 | 2026-01-27 | Generation Bio Co. | Lipids and nanoparticle compositions thereof |
| AU2021307952A1 (en) * | 2020-07-17 | 2023-03-02 | Generation Bio Co. | Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof |
-
2021
- 2021-03-26 US US17/913,498 patent/US12534435B2/en active Active
- 2021-03-26 WO PCT/US2021/024413 patent/WO2021195529A2/en not_active Ceased
- 2021-03-26 EP EP21776608.8A patent/EP4125821A4/en active Pending
- 2021-03-26 KR KR1020227037604A patent/KR20220160647A/ko active Pending
- 2021-03-26 CA CA3173126A patent/CA3173126A1/en active Pending
- 2021-03-26 CN CN202180037847.5A patent/CN115916163A/zh active Pending
- 2021-03-26 MX MX2022011988A patent/MX2022011988A/es unknown
- 2021-03-26 BR BR112022019369A patent/BR112022019369A2/pt unknown
- 2021-03-26 JP JP2022558110A patent/JP7746280B2/ja active Active
- 2021-03-26 IL IL296763A patent/IL296763B2/en unknown
- 2021-03-26 AU AU2021241696A patent/AU2021241696B2/en active Active
-
2024
- 2024-04-24 US US18/644,728 patent/US12252470B2/en active Active
-
2025
- 2025-01-31 US US19/042,351 patent/US20250361208A1/en active Pending
- 2025-09-17 JP JP2025154013A patent/JP2025181861A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL296763A (en) | 2022-11-01 |
| EP4125821A2 (en) | 2023-02-08 |
| WO2021195529A3 (en) | 2021-11-18 |
| JP7746280B2 (ja) | 2025-09-30 |
| WO2021195529A2 (en) | 2021-09-30 |
| KR20220160647A (ko) | 2022-12-06 |
| JP2025181861A (ja) | 2025-12-11 |
| JP2023518985A (ja) | 2023-05-09 |
| CN115916163A (zh) | 2023-04-04 |
| IL296763B1 (en) | 2025-12-01 |
| IL296763B2 (en) | 2026-04-01 |
| BR112022019369A2 (pt) | 2022-12-13 |
| US20250361208A1 (en) | 2025-11-27 |
| US20240294474A1 (en) | 2024-09-05 |
| CA3173126A1 (en) | 2021-09-30 |
| EP4125821A4 (en) | 2024-06-26 |
| AU2021241696B2 (en) | 2026-08-06 |
| US12252470B2 (en) | 2025-03-18 |
| US12534435B2 (en) | 2026-01-27 |
| AU2021241696A1 (en) | 2022-12-01 |
| US20230159459A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019369A2 (pt) | Lipídios e composições de nanopartículas dos mesmos | |
| CO2023015501A2 (es) | Lípidos catiónicos y composiciones de estos | |
| MX2022006033A (es) | Lipidos ionizables y composiciones de nanoparticulas de estos. | |
| MX2023014855A (es) | Lípidos catiónicos y composiciones de estos. | |
| MX2022014484A (es) | Lipidos nuevos y composiciones de nanoparticulas de estos. | |
| CY1125154T1 (el) | Ενωσεις και συνθεσεις για ενδοκυτταρικη χορηγηση θεραπευτικων παραγοντων | |
| ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
| MX2022003285A (es) | Compuestos lipidos que contienen carbonato y composiciones para suministro intracelular de agentes terapeuticos. | |
| BR112021021313A2 (pt) | Lipídios de amina ionizáveis e nanopartículas de lipídio | |
| CL2023000204A1 (es) | Composiciones dirigidas al músculo genomodificadas | |
| MX2022003402A (es) | Grupos principales de compuestos lipídicos y composiciones para la administración intracelular de agentes terapéuticos. | |
| CY1119148T1 (el) | Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης | |
| CO2021000456A2 (es) | Compuestos antagonistas de pcsk9 referencia recíproca a solicitudes relacionadas | |
| CY1123807T1 (el) | Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna | |
| CY1118821T1 (el) | Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες | |
| MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
| CY1116075T1 (el) | Νεες συνθεσεις λιποσωματων | |
| AR037666A1 (es) | Metodo para la identificacion de enzimas marcadores tumorales | |
| CO2023012198A2 (es) | Moduladores de sting (estimulador de genes de interferón) | |
| CL2022000319A1 (es) | Derivados de amidas híbridas de anfotericina b | |
| CL2022002580A1 (es) | Agentes de arni para inhibir la expresión de pnpla3, composiciones farmacéuticas de estos, y métodos de uso. | |
| MX2019012033A (es) | Regímenes de dosificación y composiciones y métodos relacionados. | |
| UY31294A1 (es) | Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos | |
| DK1526840T3 (da) | Nanopartikler til DNA administration til et målorgan | |
| BR112013003658A2 (pt) | compostos antivirais contendo azida |